|
When entering into a commercialisation project with Birkeland Innovation, Birkeland will ask you and your co-inventor(s) to sign an agreement concerning how a potential income should be shared. You will also be asked to sign an agreement regulating the relationship between the inventor(s), the University of Oslo (UiO) and Birkeland Innovation.
The University of Oslo has implemented an IPR policy, regulating the distribution of a potential net income from out-licensing of technology:
1/3 goes to inventor(s)/employee(s)
1/3 goes to UiO with the following distribution:
- 25 % to the research group as a research fund
- 8 % to the Faculty for innovation related work
1/3 goes to Birkeland Innovation
You can read more about UiO’s IPR policy at UiOs web pages.
Please note that the above-mentioned distribution of a potential net income is based on out-licensing (or sale) of the technology. If it is decided that a company should be set up, different models will be applied.
Different inventions require different commercialisation strategies. Birkeland Innovation creates solutions for continuous commercial development of all projects in our portfolio. Depending on the technology, the commercialization process is directed towards creation of a new spin-out company or transfer to the industry through a license agreement (or sale).
Developing a commercialisations strategy often includes filing a patent application, obtaining public and private funding and seeking information and feedback on market risks from various sources such as potential licensees and venture capital firms. In parallel, Birkeland Innovation will be involved in planning and execution of continuous development of the scientific results towards a product.
Birkeland Innovation finances and supports the commercialization process by providing project management, funding for patent protection, legal advices and business development, and seeks financing for the business and product development until the project is ready to become a spin-out company or is out-licensed (or sold) to the industry. Our experience has shown that patent protection and early seed investments, as well as continuous scientific development, are all crucial success factors in business development.
There are no guarantees of success for new technology companies. Experience has shown that early seed investments in business development and patent protection as well as continuous scientific development are all crucial success factors. Chances are further improved by good business strategies implemented by a strong management team. Although the research may form the basis of a spin-out company, to succeed the company will also need a strong commercial strategy implemented by people with relevant experience and knowledge. Birkeland Innovation therefore focuses on bringing the right people together and forms a strong team around the technology in order to bring it from idea to product or service on the market.
The Birkeland team together with the inventors creates a plan for commercialization with the goal to develop a strategy for the shortest possible route to successful exit. The strategies of the spin-out companies are usually enabling early exit opportunities through partnerships with existing international companies that provide expertise and an established international sale force.
Simultaneously with the creation of a business plan the project teams are planning the development of the scientific results towards a product, and tuning the product towards a good market. The development work is also synchronized with the development of the patent portfolio and the project team assures that any new findings are protected. |